KR20230018474A - 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법 - Google Patents

급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법 Download PDF

Info

Publication number
KR20230018474A
KR20230018474A KR1020227046211A KR20227046211A KR20230018474A KR 20230018474 A KR20230018474 A KR 20230018474A KR 1020227046211 A KR1020227046211 A KR 1020227046211A KR 20227046211 A KR20227046211 A KR 20227046211A KR 20230018474 A KR20230018474 A KR 20230018474A
Authority
KR
South Korea
Prior art keywords
amino acids
present
free amino
pharmaceutical formulation
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227046211A
Other languages
English (en)
Korean (ko)
Inventor
사다시반 비드야사가르
아스트리드 그로쉐
시아오동 쉬
다미아노 앙골리
스테펜 제이. 가토
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인크.
엔트린직, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인크., 엔트린직, 엘엘씨 filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인크.
Publication of KR20230018474A publication Critical patent/KR20230018474A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227046211A 2020-05-29 2021-05-28 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법 Pending KR20230018474A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063032185P 2020-05-29 2020-05-29
US63/032,185 2020-05-29
US202063080470P 2020-09-18 2020-09-18
US63/080,470 2020-09-18
US202063088813P 2020-10-07 2020-10-07
US63/088,813 2020-10-07
US202163136404P 2021-01-12 2021-01-12
US63/136,404 2021-01-12
PCT/US2021/034807 WO2021243183A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Publications (1)

Publication Number Publication Date
KR20230018474A true KR20230018474A (ko) 2023-02-07

Family

ID=78722883

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227046211A Pending KR20230018474A (ko) 2020-05-29 2021-05-28 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법

Country Status (10)

Country Link
US (1) US20230201151A1 (https=)
EP (1) EP4157218A4 (https=)
JP (1) JP2023531872A (https=)
KR (1) KR20230018474A (https=)
CN (1) CN115697301A (https=)
AU (1) AU2021280328A1 (https=)
BR (1) BR112022024033A2 (https=)
CA (1) CA3177780A1 (https=)
MX (1) MX2022015044A (https=)
WO (1) WO2021243183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036277B (zh) * 2022-07-19 2023-10-31 广州国家实验室 氯离子在预防、治疗冠状病毒所致疾病中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
EP3691628A1 (en) * 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
WO2019070759A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis

Also Published As

Publication number Publication date
BR112022024033A2 (pt) 2022-12-20
US20230201151A1 (en) 2023-06-29
WO2021243183A8 (en) 2022-01-13
WO2021243183A1 (en) 2021-12-02
MX2022015044A (es) 2023-01-04
AU2021280328A1 (en) 2022-11-17
CN115697301A (zh) 2023-02-03
EP4157218A4 (en) 2024-06-26
JP2023531872A (ja) 2023-07-26
EP4157218A1 (en) 2023-04-05
CA3177780A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US20250000821A1 (en) Methods of using dipivefrin
CA3182274A1 (en) Inhaled statins for treatment of viral respiratory diseases
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
AU2016287580A1 (en) Compositions and methods for the treatment of viral infection
JP2021516219A (ja) ライノウイルス感染症の予防又は治療のための薬物
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
KR20230018474A (ko) 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
JP2024153711A (ja) 急性増悪をポリクローナル免疫グロブリンで予防または治療するための方法および組成物
JP2023524693A (ja) ラクトフェリンの投与によるＳＡＲＳ－ＣｏＶ－２ウイルス侵入の阻害およびその使用
US20040242700A1 (en) Anti-influenzal agent
US20230226056A1 (en) Compatible solutes for preventing or treating sars-cov-2 infections
WO2021252378A1 (en) Prevention or treatment of covid-19
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
EP4135685A1 (en) Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus
US20220016160A1 (en) Method for preventing or treating infection of respiratory virus utilizing gold nanoparticles
US20260007656A1 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, pulmonary arterial hypertension, adn respiratory syncytial virus
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
CN102369012B (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
JP2003155230A (ja) 抗インフルエンザ薬
WO2022146399A1 (en) Dual inhibition of sars-cov-2 virus of leukotriene ltd4 receptor antagonist montelukast
JP2005281227A (ja) インフルエンザウイルス感染症の治療および予防薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240527

Comment text: Request for Examination of Application